Scarica l'app Stockscreener
0.9018
0.90%
-0.0082
Precedente Chiudi:
$0.91
Aprire:
$0.919
Volume 24 ore:
7,959
Relative Volume:
0.15
Capitalizzazione di mercato:
$2.94M
Reddito:
-
Utile/perdita netta:
$-11.12M
Rapporto P/E:
-0.6219
EPS:
-1.45
Flusso di cassa netto:
$-8.07M
1 W Prestazione:
-14.48%
1M Prestazione:
-36.04%
6M Prestazione:
-52.54%
1 anno Prestazione:
-99.43%
Intervallo 1D:
$0.9002
$0.919
Intervallo di 1 settimana:
$0.85
$1.0619
Portata 52W:
$0.85
$348.00
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Nome
Processa Pharmaceuticals Inc
Settore
Industria
Telefono
443-776-3133
Indirizzo
7380 COCA COLA DRIVE, HANOVER
Confronta PCSA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| PCSA | 0.902 | 2.94M | 0 | -11.12M | -8.07M | -1.45 |
| VRTX | 449.99 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 593.04 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.22 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.19 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Processa Pharmaceuticals Inc Borsa (PCSA) Ultime notizie
Processa Pharmaceuticals stock hits 52-week low at $1.04 By Investing.com - Investing.com Australia
Processa Pharmaceuticals stock hits 52-week low at $1.04 - Investing.com India
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Processa Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Processa Pharmaceuticals stock hits 52-week low at $1.18 - Investing.com
Processa Pharmaceuticals stock hits 52-week low at $1.18 By Investing.com - Investing.com UK
Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results - The Manila Times
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Colorectal Cancer Pipeline Overview 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa Pharma - The Globe and Mail
Gastroparesis Treatment Market Size, Demand, Trends, Analysis - openPR
processa pharmaceuticals inc. Earnings dates - RTTNews
Analytical Lens: Exploring Processa Pharmaceuticals Inc (PCSA)’s Financial Story Through Ratios - The Dwinnex
Processa stock rallies 35% post-market on Phase 2 study update - MSN
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer - ForexTV.com
Constellation Brands, Levi Strauss And 3 Stocks To Watch Heading Into Thursday - Benzinga
Pure Storage, Inc. (NYSE:PSTG) CRO Sells $450,709.65 in Stock - Defense World
Peraso Inc’s latest rating changes from various analysts - Knox Daily
Progress Software (PRGS) Q3 Earnings and Revenues Surpass Estimates - Yahoo Finance
Progress Software Stock Jumps On Q3 Earnings: Revenue Beat, EPS Beat, Raised Guidance And More - TradingView
Progress Software Corp (PRGS) Q3 2024 Earnings: EPS of $0.65 Bea - GuruFocus.com
Perrigo shares downgraded amid restructuring efforts - Investing.com India
Jefferies Financial Group Boosts Pacira BioSciences (NASDAQ:PCRX) Price Target to $18.00 - Defense World
A Look at Pacira BioSciences Inc (PCRX) Shares in the Recent Past Indicates Growth - SETE News
Check out these key findings about Privia Health Group Inc (PRVA) - SETE News
Sagefield Capital LP Acquires 1,023,527 Shares of Permian Resources Co. (NASDAQ:PR) - Defense World
Precigen Inc (PGEN)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Monitoring Perrigo Company plc (PRGO) after recent insider movements - Knox Daily
Pacira price target raised to $18 from $15 at Jefferies - TipRanks
Get in on PureCycle Technologies Inc’s (PCT) buy-in window today! - SETE News
72,064 Shares in Primoris Services Co. (NASDAQ:PRIM) Acquired by Appian Way Asset Management LP - MarketBeat
Financial Snapshot: Analyzing PureCycle Technologies Inc (PCT)’s Key Ratio Metrics - The Dwinnex
Primoris Services Co. (NASDAQ:PRIM) Shares Sold by Paradigm Capital Management Inc. NY - Defense World
Dimensional Fund Advisors LP Has $108.58 Million Position in Perdoceo Education Co. (NASDAQ:PRDO) - Defense World
Rs 5,890 Crore Order Book: Construction Company Secures Orders Worth Rs 554.92 Crore, FY25 Order Inflows Reach Rs 1,444.91 Crore – FIIs and DIIs Significantly Increase Stake - Dalal Street Investment Journal
Should We Be Delighted With Poste Italiane S.p.A.'s (BIT:PST) ROE Of 18%? - Simply Wall St
ProSiebenSat.1 Media (OTCMKTS:PBSFY) Shares Up 8.7% - Defense World
Precigen Inc (PGEN) may enjoy gains as insiders got busy in the recent days - Knox Daily
A look into Prothena Corporation plc (PRTA)’s deeper side - SETE News
Understanding the Risks of Investing in Privia Health Group Inc (PRVA) - Knox Daily
Is PureCycle Technologies Inc (PCT) a good investment opportunity? - US Post News
Top Wall Street Forecasters Revamp Progress Software Price Expectations Ahead Of Q3 Earnings - Benzinga
Morse Asset Management Inc Purchases 9,255 Shares of Primoris Services Co. (NASDAQ:PRIM) - MarketBeat
Vanguard Personalized Indexing Management LLC Has $1.19 Million Holdings in POSCO Holdings Inc. (NYSE:PKX) - Defense World
Victory Capital Management Inc. Boosts Stake in Privia Health Group, Inc. (NASDAQ:PRVA) - Defense World
Pacer Advisors Inc. Purchases 518,048 Shares of Perdoceo Education Co. (NASDAQ:PRDO) - MarketBeat
Federated Hermes Inc. Acquires Shares of 43,861 Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Shares Acquired by Rhumbline Advisers - Defense World
Insider Selling: Primoris Services Co. (NASDAQ:PRIM) Director Sells 25,000 Shares of Stock - MarketBeat
Nkcfo LLC Acquires 20,525 Shares of Primoris Services Co. (NASDAQ:PRIM) - Defense World
Primoris Services Co. (NASDAQ:PRIM) Director John P. Schauerman Sells 25,000 Shares - Defense World
FDA Approval Propels ZVRA To 52-week High, ADMA, CPRX, TVTX Also Reach New Peaks - Nasdaq
Processa Pharmaceuticals Inc Azioni (PCSA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Processa Pharmaceuticals Inc Azioni (PCSA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Young David | Pres. Research & Development |
Feb 06 '24 |
Buy |
2.53 |
20,000 |
50,504 |
58,387 |
| Lin Patrick | Chief Business - Strategy Off |
Jan 31 '24 |
Buy |
2.37 |
2,500 |
5,925 |
25,978 |
| Lin Patrick | Chief Business - Strategy Off |
Feb 01 '24 |
Buy |
2.40 |
1,500 |
3,600 |
27,478 |
| Ng George K | Chief Executive Officer |
Jan 30 '24 |
Buy |
2.70 |
10,000 |
27,000 |
20,000 |
| Yorke Justin W | Director |
Jan 30 '24 |
Buy |
2.69 |
8,000 |
21,544 |
31,232 |
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):